Agios to Webcast Conference Call of First Quarter 2024 Financial Results on May 2, 2024 Read more about Agios to Webcast Conference Call of First Quarter 2024 Financial Results on May 2, 2024
Agios Publishes 2024 Environmental, Social and Governance (ESG) Report Read more about Agios Publishes 2024 Environmental, Social and Governance (ESG) Report
Agios to Present at the Leerink Partners Global Biopharma Conference on March 12, 2024 Read more about Agios to Present at the Leerink Partners Global Biopharma Conference on March 12, 2024
Agios to Present at the TD Cowen 44th Annual Health Care Conference on March 4, 2024 Read more about Agios to Present at the TD Cowen 44th Annual Health Care Conference on March 4, 2024
Agios Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights Read more about Agios Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
Agios to Webcast Conference Call of Fourth Quarter and Year End 2023 Financial Results on February 15, 2024 Read more about Agios to Webcast Conference Call of Fourth Quarter and Year End 2023 Financial Results on February 15, 2024
Agios Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio Read more about Agios Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio
Agios Announces Phase 3 ENERGIZE Study of Mitapivat Met Primary Endpoint and Both Key Secondary Endpoints in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia Read more about Agios Announces Phase 3 ENERGIZE Study of Mitapivat Met Primary Endpoint and Both Key Secondary Endpoints in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia
Agios to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024 Read more about Agios to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024
Agios Presents Positive Results from Phase 2 Portion of the RISE UP Pivotal Study in Sickle Cell Disease at 65th ASH Annual Meeting and Exposition Read more about Agios Presents Positive Results from Phase 2 Portion of the RISE UP Pivotal Study in Sickle Cell Disease at 65th ASH Annual Meeting and Exposition